Bioluminescence imaging of Hepatitis C virus NS3/4A serine protease activity in cells and living animals

被引:22
作者
Wang, Licui [1 ]
Fu, Qiuxia [1 ]
Dong, Yafeng [1 ]
Zhou, Yong [1 ]
Jia, Shuaizheng [1 ]
Du, Juan [1 ]
Zhao, Fang [1 ]
Wang, Yingli [1 ]
Wang, Xiaohui [1 ]
Peng, Jianchun [1 ]
Yang, Shuhua [1 ]
Zhan, Linsheng [1 ]
机构
[1] Beijing Inst Transfus Med, Lab Blood Borne Virus, Beijing 100850, Peoples R China
基金
国家高技术研究发展计划(863计划);
关键词
NS3/4A protease; Split firefly luciferase complementation strategy; In vivo imaging; RNA REPLICATION; IN-VIVO; INFECTION; CULTURE; ASSAY; INTERFERENCE; REPLICON; VIREMIA; LINES;
D O I
10.1016/j.antiviral.2010.04.010
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The lack of robust small animal models has been an obstacle to the screening of Hepatitis C virus (HCV) NS3/4A protease inhibitors in vivo. Here, we described a reporter assay system for in vivo noninvasive imaging of NS3/4A serine protease activity using split firefly luciferase complementation strategy. The reporter construct ANIuc(NS5A/B)BCluc constitutes the split N- and C-terminal fragments of luciferase, fused to interacting peptides, pepA and pepB, respectively, with an intervening HCV NS3/4A cleavage motif of NSSA/B. we proved that the reporter molecule could be proteolytically cleaved by NS3/4A at the NS5A/B motif in cells and living animals. Association of pepA and pepB brought inactive fragments of luciferase into close proximity, thereby restoring bioluminescence activity. The increase in luciferase activity was proportional to the dose of active NS3/4A protease. The ANIuc(NS5A/B)BCluc reporter also could be used to detect the activity of NS3/4A-specific shRNA and IFN-alpha. Therefore, the reporter assay system using split firefly luciferase complementation strategy should prove useful for evaluating NS3/4A protease activity in cells and living animals. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:50 / 56
页数:7
相关论文
共 50 条
  • [41] In Vitro Susceptibility of Hepatitis C Virus Genotype 1 through 6 Clinical Isolates to the Pangenotypic NS3/4A Inhibitor Voxilaprevir
    Han, Bin
    Parhy, Bandita
    Zhou, Eric
    Hsieh, David
    Camus, Gregory
    Martin, Ross
    Svarovskaia, Evguenia S.
    Mo, Hongmei
    Dvory-Sobol, Hadas
    JOURNAL OF CLINICAL MICROBIOLOGY, 2019, 57 (04)
  • [42] In Vitro Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir
    Jiang, Min
    Mani, Nagraj
    Lin, Chao
    Ardzinski, Andrzej
    Nelson, Michelle
    Reagan, Dugan
    Bartels, Doug
    Zhou, Yi
    Nicolas, Olivier
    Rao, B. Govinda
    Mueh, Ute
    Hanzelka, Brian
    Tigges, Ann
    Rijnbrand, Rene
    Kieffer, Tara L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 6236 - 6245
  • [43] Hepatitis C virus core or NS3/4A protein expression preconditions hepatocytes against oxidative stress and endoplasmic reticulum stress
    Rios-Ocampo, W. Alfredo
    Daemen, Toos
    Buist-Homan, Manon
    Faber, Klaas Nico
    Navas, Maria-Cristina
    Moshage, Han
    REDOX REPORT, 2019, 24 (01) : 17 - 26
  • [44] Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)
    McPhee, Fiona
    Sheaffer, Amy K.
    Friborg, Jacques
    Hernandez, Dennis
    Falk, Paul
    Zhai, Guangzhi
    Levine, Steven
    Chaniewski, Susan
    Yu, Fei
    Barry, Diana
    Chen, Chaoqun
    Lee, Min S.
    Mosure, Kathy
    Sun, Li-Qiang
    Sinz, Michael
    Meanwell, Nicholas A.
    Colonno, Richard J.
    Knipe, Jay
    Scola, Paul
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (10) : 5387 - 5396
  • [45] Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
    Salam, Kazi Abdus
    Akimitsu, Nobuyoshi
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [46] Novel, potent and orally bioavailable indolizidinone-derived inhibitors of the hepatitis C virus NS3 protease
    Clarke, Michael O.
    Byun, Daniel
    Chen, Xiaowu
    Doerffler, Edward
    Leavitt, Stephanie A.
    Sheng, X. Christopher
    Yang, Cheng Y.
    Kim, Choung U.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) : 1095 - 1098
  • [47] PBDE: Structure-Activity Studies for the Inhibition of Hepatitis C Virus NS3 Helicase
    Salam, Kazi Abdus
    Furuta, Atsushi
    Noda, Naohiro
    Tsuneda, Satoshi
    Sekiguchi, Yuji
    Yamashita, Atsuya
    Moriishi, Kohji
    Nakakoshi, Masamichi
    Tani, Hidenori
    Roy, Sona Rani
    Tanaka, Junichi
    Tsubuki, Masayoshi
    Akimitsu, Nobuyoshi
    MOLECULES, 2014, 19 (04): : 4006 - 4020
  • [48] Structure-activity relationships of 4-hydroxy-4-biaryl-proline acylsulfonamide tripeptides: A series of potent NS3 protease inhibitors for the treatment of hepatitis C virus
    Wang, Alan Xiangdong
    Chen, Jie
    Zhao, Qian
    Sun, Li-Qiang
    Friborg, Jacques
    Yu, Fei
    Hernandez, Dennis
    Good, Andrew C.
    Klei, Herbert E.
    Rajamani, Ramkumar
    Mosure, Kathy
    Knipe, Jay O.
    Li, Danshi
    Zhu, Jialong
    Levesque, Paul C.
    McPhee, Fiona
    Meanwell, Nicholas A.
    Scola, Paul M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (03) : 590 - 596
  • [49] Natural presence of NS3 protease R155K hepatitis C virus variants with decreased sensitivity to protease inhibitors
    Colson, Philippe
    Purgus, Raj
    Borentain, Patrick
    Gerolami, Rene
    JOURNAL OF CLINICAL VIROLOGY, 2012, 53 (02) : 178 - 180
  • [50] Conditional Inducible Triple-Transgenic Mouse Model for Rapid Real-Time Detection of HCV NS3/4A Protease Activity
    Yao, Min
    Lu, Xin
    Lei, Yingfeng
    Yang, Jing
    Zhao, Haiwei
    Qiao, Qinghua
    Han, Peijun
    Xu, Zhikai
    Yin, Wen
    PLOS ONE, 2016, 11 (03):